Download Brochure
Table of Content
Get a Price
March 2025
.webp)
Principal Consultant
Reviewed By
The global influenza vaccine market size is calculated at USD 8.49 billion in 2024, grew to USD 9.08 billion in 2025, and is projected to reach around USD 16.73 billion by 2034. The market is expanding at a CAGR of 7.02% between 2025 and 2034. The high occurrence of seasonal flu and growing recommendations for vaccination to prevent the illness, as well as the increasing geriatric population, drive the market growth, with complications arising from infection also contributing to market growth.
Influenza is a contagious viral infection that targets both the upper and lower respiratory systems. It is characterized by symptoms such as fever, chills, muscle aches, general fatigue, and discomfort in the head and abdomen. The increasing number of severe influenza cases, particularly among children, is driving market growth. The Global Influenza Program's emphasis on vaccination as a preventive measure is also driving this expansion. Combination vaccines, which protect against various strains of viruses, are gaining popularity due to their convenience and effectiveness. Additionally, the emergence of mRNA vaccines, which use advanced technology to create a stronger immune response, is a promising development in the market. According to estimates from the CDC, published in October 2023, seasonal influenza affects approximately one billion people globally each year, with around 3-5 million of those cases resulting in chronic illnesses.
Artificial Intelligence (AI) is transforming the market by accelerating vaccine development, improving production, and optimizing distribution. AI helps identify potential vaccine candidates, predict viral mutations, and enhance clinical trial designs. It can also predict which flu strains will dominate in a given season, ensuring the development of more effective vaccines. In vaccine production, AI streamlines processes, reduces costs, and improves supply chain efficiency for timely delivery. This integration is poised to make flu vaccines more adaptive and accessible.
Increasing Prevalence and Incidence of Influenza
The increasing prevalence of influenza drives the vaccine market by increasing the demand for preventive measures. Recommendations from health organizations for widespread vaccination, along with growing awareness of flu-related risks, especially for vulnerable groups, further fuel the need for vaccines. Additionally, advancements in vaccine technology and the expansion of vaccination programs in various regions contribute to the influenza vaccine market’s growth.
Difficulty in Diagnosis of Influenza
Accurate and timely diagnosis is crucial for determining the need for vaccination, especially during flu season when symptoms overlap with other respiratory illnesses. Delays or misdiagnoses can lead to a lower vaccination rate, as individuals may not seek vaccination until the infection becomes severe. This uncertainty in diagnosis can also hinder healthcare professionals' ability to target the right population for vaccination, ultimately slowing down market growth.
Global Immunization Initiatives
Global immunization initiatives present a significant opportunity for the influenza vaccine market. As governments and international organizations, such as the World Health Organization (WHO), ramp up efforts to combat infectious diseases through mass vaccination campaigns, the demand for influenza vaccines increases. These initiatives aim to expand vaccine access, especially in underserved and high-risk populations, driving market growth. Additionally, with the push for universal health coverage and global health security, the expansion of immunization programs in both developed and developing nations creates a broader market for flu vaccines. These global efforts help increase awareness, improve vaccination rates, and ensure wider distribution, further boosting the demand for influenza vaccines.
By vaccine type, the inactivated vaccines segment held the largest share of the influenza vaccine market in 2024 and is estimated to be the fastest-growing during the forecast period. Inactivated vaccines are considered safer for high-risk populations, including the elderly, children, pregnant women, and individuals with immunocompromising conditions, as they do not contain live viruses. The advancements in manufacturing processes have made inactivated vaccines more widely available and cost-effective. Inactivated vaccines administered to children aged 6 to 35 months showed a strong antibody response even one year after the initial vaccination. Furthermore, these vaccines helped lower the risk of contracting influenza A and B infections later on.
By vaccine type, the live attenuated vaccine segment is estimated to grow at a significant rate in the market during the forecast period. These vaccines, which contain weakened forms of the virus, typically offer a stronger and longer-lasting immune response compared to inactivated vaccines. They are especially popular for healthy individuals, including children and adults, as they can provide broader protection with just one dose. These vaccines are easy to administer, often in a needle-free nasal spray form, which increases patient compliance and convenience, driving their fast market growth.
By indication, the quadrivalent segment was dominant in the influenza vaccine market in 2024 and is expected to grow at the fastest rate during the forecast period due to its ability to protect against four different influenza strains, including two A strains and two B strains. Quadrivalent vaccines are preferred by healthcare providers and recommended by organizations like the WHO, driving higher demand and market share. Their comprehensive coverage ensures better protection, which has contributed to their dominance.
For instance,
By indication, the trivalent segment is expected to witness significant growth in the market over the coming years. While quadrivalent vaccines provide broader coverage, trivalent vaccines are more affordable, making them a popular choice, particularly in low- and middle-income countries. According to the WHO, over 50% of global seasonal flu vaccines administered are trivalent, further supporting their widespread use. Additionally, their ability to be produced in large quantities quickly, along with ongoing recommendations for specific populations, contributes to their increasing adoption and growth in the influenza vaccine market.
By age group, the adult segment registered its dominance over the global influenza vaccine market in 2024. Adults, particularly those over 65 and those with chronic health conditions, are at a higher risk of severe flu complications, making vaccination essential. Increased awareness of the flu’s potential impact on working-age populations and older adults, along with widespread recommendations from health organizations for annual vaccination, has led to higher demand in this age group. Additionally, many adults are more likely to seek preventive care, driving the growth of vaccines in this segment. The availability of vaccines tailored for adults, such as higher-dose and adjuvanted options, further supports this dominance.
By age group, the pediatric segment is expected to grow at a lucrative rate between 2025 and 2034. Increased awareness of the importance of early vaccination and a growing focus on childhood health are driving demand for flu vaccines in children. Pediatric populations are more vulnerable to severe flu-related complications, making vaccination a priority. Government initiatives and health organizations are also focusing on expanding vaccine coverage for children, contributing to higher vaccine uptake. Additionally, advancements in vaccine formulations tailored specifically for children, such as needle-free options and age-appropriate doses, are improving convenience and boosting demand, further fueling growth in this segment.
By route of administration, the injection segment held the major share of the influenza vaccine market in 2024. Injections, particularly those administered intramuscularly or subcutaneously, are the most widely recognized and trusted method for vaccine administration, providing reliable immune responses. This method is well-supported by healthcare professionals and is recommended by global health organizations, such as the WHO and CDC. Additionally, injections are commonly used for both inactivated and adjuvanted vaccines, which are popular in many regions. The injection route also benefits from extensive infrastructure for distribution and administration, further solidifying its market dominance.
By route of administration, the nasal spray segment is estimated to grow at the fastest CAGR during the predicted timeframe. Nasal spray vaccines are needle-free, making them more appealing, particularly for children and needle-phobic individuals. This method is easier to administer, which improves patient compliance and increases vaccination rates. The growing preference for needle-free options, along with advancements in nasal spray formulations to enhance efficacy and safety, is driving the segment's rapid growth. Additionally, the potential for faster mass distribution, especially in public health campaigns, further supports the increasing demand for nasal spray vaccines.
For instance,
By distribution, the hospitals and pharmacies segment was dominant in the influenza vaccine market in 2024. Individuals regularly visit health services, including for vaccinations, which provide efficient and organized systems for administering vaccines and offer immediate medical support. In January 2023, around 40.76 million flu vaccine doses were distributed to U.S. pharmacies for adults aged 18 and older, marking an increase of 1.4 million doses compared to January 2022. In contrast, U.S. physician offices received approximately 26.58 million doses, which was 2.9 million fewer than the previous year.
By distribution, the government and institutional segment is projected to grow at the fastest rate in the market during the forecast period. Governments worldwide are expanding vaccination efforts, especially in schools, workplaces, and community centers, to ensure broader vaccine coverage. Institutional settings, such as public health organizations, military facilities, and large healthcare systems, also contribute to this growth by administering vaccines to large populations quickly and efficiently. Additionally, funding from government programs and international health organizations is boosting the availability and distribution of vaccines, driving rapid growth in this segment.
North America led the influenza vaccine market share by 53% in 2024, driven by its strong healthcare infrastructure, widespread access to vaccines, and government-backed vaccination programs. High vaccination rates, public awareness, and the presence of major vaccine manufacturers further supported its market dominance. Additionally, the region’s higher prevalence of seasonal flu boosted the demand for vaccines. According to WHO data from December 2023, there were approximately 150,865 confirmed influenza cases, with 149,704 cases caused by influenza A and 161 cases caused by influenza B.
The U.S. market is growing due to strong government support, increased public awareness of flu risks, and easy access to healthcare infrastructure. Seasonal flu outbreaks, advancements in vaccine technology, and a wider variety of vaccine options also drive demand, making vaccines more accessible and effective. In June 2024, the NIH initiated clinical trials for FluMos-v1, a vaccine candidate in the U.S. This vaccine works by triggering the production of antibodies against various influenza virus strains through the presentation of specific proteins from the influenza virus.
The Canadian market is experiencing growth driven by increasing demand for flu prevention, particularly among high-risk groups. Innovations in vaccine technology and government efforts to improve accessibility, particularly in remote areas, are also driving market expansion. In December 2023, the Public Health Agency of Canada reported that Canada had recorded approximately 34,413 influenza cases between August and December 2022 such increased cases drive the market.
Asia Pacific is estimated to grow at the fastest rate in the market during the forecast period. Rising healthcare investments, increasing awareness, and expanding vaccination programs. In February 2023, SK Bioscience announced a USD 261 million investment to build the Songdo Global Research and Process Development Center for vaccine research and development. The region’s large population and higher transmission rates contribute to a greater burden of respiratory infections, such as influenza, as noted by the Singapore Ministry of Health.
The Chinese market is expanding due to a significant rise in healthcare investments and the government’s push for widespread vaccination campaigns. China’s large population, combined with rapid urbanization and a rise in flu cases, is driving the need for more accessible and efficient vaccination solutions. Additionally, as China focuses on improving its public health systems and tackling seasonal flu outbreaks, there has been a surge in demand for flu vaccines. The development of more effective vaccines and increasing participation in immunization programs is further boosting market growth.
The Indian market is growing due to increasing awareness of the importance of flu prevention, particularly in light of the rising incidence of respiratory infections. Government initiatives, such as expanded immunization programs and national vaccination campaigns, are driving greater vaccine adoption. Additionally, the availability of affordable vaccine options, along with advancements in vaccine technology, is further fueling market growth. Rising cases of seasonal flu, particularly among vulnerable populations, also contribute significantly to the market’s expansion.
Europe is expected to experience significant growth in the influenza vaccine market during the forecast period, driven by government initiatives, increasing flu awareness, and the higher vulnerability of the aging population to flu. Improved vaccine access, advancements in formulations, and rising flu outbreaks are also driving demand. Strict regulatory standards oversee product development, guaranteeing the safety and effectiveness of influenza prevention methods.
The German market is growing due to increased awareness of flu prevention and government-backed vaccination campaigns. The country’s well-established healthcare system ensures easy access to vaccines, particularly for high-risk groups, such as the elderly. Rising flu cases and seasonal outbreaks further drive demand for vaccines. Additionally, advancements in vaccine formulations and a growing emphasis on preventive healthcare contribute to the market’s expansion in Germany.
The UK market is expanding due to the country’s robust healthcare infrastructure and effective public health initiatives. The introduction of innovative flu vaccines, including high-dose and adjuvanted options, is driving market growth. The UK's focus on improving vaccination coverage, especially during flu season, and the increase in public awareness about the effectiveness of flu shots are also key factors. Additionally, government policies encouraging flu vaccination as a preventive measure have led to higher vaccine uptake.
In July 2024, Sinergium Biotech in Argentina aims to accelerate the development of H5N1 mRNA vaccines for low- and middle-income countries (LMICs) through the WHO and Medicines Patent Pool’s mRNA Technology Transfer Programme. The initiative focuses on building vaccine production capacity and improving pandemic preparedness. Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, stated, "This project ensures the world is better prepared for future pandemics." Charles Gore, Executive Director of MPP, added, "It enables LMICs to lead development and foster collaboration for better preparedness."
By Vaccine Type
By Indication
By Age Group
By Route of Administration
By Distribution
By Region
March 2025
March 2025
March 2025
March 2025
Schedule a Meeting